Close
CDMO Safety Testing 2026
Novotech

To Accredit Medical Devices In The UK, MHRA Selects DEKRA

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Bristol Myers Squibb Integrates AI to Advance Manufacturing Quality Systems

Bristol Myers Squibb has entered into a strategic agreement...

QIAGEN and NVIDIA Join Forces to Advance AI-Driven Drug Discovery

QIAGEN's Digital Insights bioinformatics division is set to integrate...
- Advertisement -

The three current UK-approved bodies have been joined by DEKRA Certification UK, according to the Medicines and Healthcare Products Regulatory Agency (MHRA), enhancing the UK’s capacity to handle conformity evaluations for medical devices. As the first institution to accomplish the new designation procedure, DEKRA is now authorised to carry out evaluations of general medical equipment, or Part II designation.

An approved body is a group that has been given permission by the MHRA to check whether manufacturers and their medical devices meet the requirements set out in the UK Medical Devices Regulations 2002. Manufacturers must submit an application to a UK-approved organisation, with the exception of the absolute lowest-risk devices. Their products can only be sold in England, Wales, and Scotland after receiving UK Conformity Assessed (UKCA) certification.

The goal of the MHRA’s thorough assessment process is to make sure that any organisations that wish to certify medical devices are stable, capable of conducting fair and objective evaluations, have a suitable quality management process in place to support them, have the resources to conduct the evaluations, and have mechanisms and ongoing credentialsย in place to comply with the relevant regulatory requirements. The recognised authority will give the necessary certification following an adequate evaluation, enabling producers to apply the UKCA logo to their products before releasing them onto the market.

This is a huge milestone in their commitment to ensuring individuals all across the UK get access to the high-quality medical equipment they need to protect their health, said Dr. Laura Squire who is the chief healthcare quality and access officer at MHRA.

The growth of the UK’s medical device regulatory framework depends on approved organisations, which play a crucial role in the supply of medical equipment. The teams have put in a tremendous amount of effort to get to this point, and this has been a huge piece of work, she continued.

An additional six organisations are currently through the assessment process, while numerous other organisations are actively engaged in the process of getting prepared to send their initial submission.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast โ€“ stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Latest stories

Related stories

Bristol Myers Squibb Integrates AI to Advance Manufacturing Quality Systems

Bristol Myers Squibb has entered into a strategic agreement...

QIAGEN and NVIDIA Join Forces to Advance AI-Driven Drug Discovery

QIAGEN's Digital Insights bioinformatics division is set to integrate...

Bioprocess Analytics Improving Biologics Manufacturing

The immense complexity of modern biopharmaceutical production is being navigated through the strategic and systematic application of bioprocess analytics improving biologics manufacturing. By leveraging real-time data streams and advanced monitoring tools, manufacturers can gain a granular, molecular-level understanding of cellular behavior and the surrounding environmental conditions within the bioreactor. This proactive, data-driven approach allows for immediate, automated adjustments that optimize therapeutic yield, ensure absolute product consistency, and significantly streamline the arduous path toward commercial-scale production in a highly regulated global environment.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป